Emsam Related Published Studies
Well-designed clinical trials related to Emsam (Selegiline Transdermal)
The relationship between depression and regional cerebral blood flow in Parkinson's disease and the effect of selegiline treatment. [2011.07]
A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers. [2010.03.01]
A double-blind, placebo-controlled, randomized clinical trial of oral selegiline
hydrochloride for smoking cessation in nicotine-dependent cigarette smokers. [2010]
Selegiline and oxidative stress in HIV-associated cognitive impairment. [2009.12.08]
Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. [2008.03]
A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression. [2008]
Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090. [2007.11]
Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. [2007.10]
A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. [2007.09.25]
Selegiline orally disintegrating tablets in patients with Parkinson disease and "wearing off" symptoms. [2007.09]
Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease. [2007.04]
Selegiline Transdermal System: An Examination of the Potential for CYP450-Dependent Pharmacokinetic Interactions With 3 Psychotropic Medications. [2007.02]
Effects of a tyramine-enriched meal on blood pressure response in healthy male volunteers treated with selegiline transdermal system 6 mg/24 hour. [2007.01]
Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials. [2007]
Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence. [2006.12.01]
Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. [2006.12]
Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. [2006.09]
A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. [2003.10]
A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. [2003.02]
Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. [2002.11]
Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. [2000.01.11]
Well-designed clinical trials possibly related to Emsam (Selegiline Transdermal)
Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial. [2014]
Milestones in Parkinson's disease therapeutics. [2011.05]
Differences in smoking expectancies in smokers with and without a history of major depression. [2011.04]
Clinical, laboratory, and neuroimaging characteristics of fatigue in HIV-infected individuals. [2011.02]
Differences in smoking expectancies in smokers with and without a history of
major depression. [2011]
Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline. [2010.12]
The role of rasagiline in the treatment of Parkinson's disease. [2010.05.25]
Efficacy of psychostimulant drugs for cocaine dependence. [2010.02.17]
Clinical pharmacology tyramine challenge study to determine the selectivity of
the monoamine oxidase type B (MAO-B) inhibitor rasagiline. [2010]
A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. [2009.12.15]
Role of rasagiline in treating Parkinson's disease: Effect on disease progression. [2009.08]
Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. [2009.05]
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. [2008.08.12]
Monamine oxidase inhibitors: current and emerging agents for Parkinson disease. [2007.05]
Other research related to Emsam (Selegiline Transdermal)
Comparative efficacy of selegiline versus rasagiline in the treatment of early
Parkinson's disease. [2014]
Selegiline Transdermal System (STS) as an Aid for Smoking Cessation. [2011.08.16]
Selegiline use is associated with a slower progression in early Parkinson's disease as evaluated by Hoehn and Yahr Stage transition times. [2011.03]
Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease. [2011.02]
The relationship between depression and regional cerebral blood flow in
Parkinson's disease and the effect of selegiline treatment. [2011]
Transdermal iontophoretic delivery of selegiline hydrochloride, in vitro. [2010.11]
Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy. [2010.09]
Marked improvement in Segawa syndrome after L-dopa and selegiline treatment. [2010.05]
Transdermal selegiline in patients receiving electroconvulsive therapy. [2010.03]
Early addition of selegiline to L-Dopa treatment is beneficial for patients with Parkinson disease. [2010.01]
Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. [2010.01]
Failure to improve cigarette smoking abstinence with transdermal selegiline +
cognitive behavior therapy. [2010]
[Slowing the age-induced decline of brain function with prophylactic use of (-)-deprenyl (Selegiline, Jumex). Current international view and conclusions 25 years after the Knoll's proposal] [2009.12]
[Severe apathy following head injury: improvement with Selegiline treatment] [2009.12]
A phase 1 trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion. [2009.08.01]
Serotonin toxicity caused by moclobemide too soon after paroxetine-selegiline. [2009.08]
Selegiline shortage: Causes and costs of a generic drug shortage. [2009.07.21]
Selegiline transdermal system: a novel treatment option for major depressive disorder. [2009.07]
Investigation of oral selegiline and rasagiline administration on QT interval in conscious rabbits. [2009.03]
Orally disintegrating selegiline for the treatment of Parkinson's disease. [2008.11]
[Comparison of dissolution profile and plasma concentration-time profile of the thalidomide formulations made by Japanese, Mexican and British companies] [2008.10]
Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35). [2008.07.19]
Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. [2008.06]
Selegiline reduces cisplatin-induced neuronal death in neuroblastoma cells. [2008.05]
The selegiline transdermal system in major depressive disorder: A systematic review of safety and tolerability. [2008.01]
Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline. [2008]
Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale. [2007.12]
Zydis selegiline in the management of Parkinson's disease. [2007.10]
Selegiline transdermal system: current awareness and promise. [2007.08.15]
Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers. [2007.08]
The selegiline transdermal system in major depressive disorder: A systematic review of safety and tolerability. [2007.06.11]
Transdermal selegiline. [2007.06]
The role of selegiline in the treatment of negative symptoms associated with schizophrenia. [2007.05]
Selegiline and blood pressure in patients with Parkinson's disease. [2007.02]
Selegiline transdermal system: in the treatment of major depressive disorder. [2007]
Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects. [2006.08]
Transdermal selegiline: the new generation of monoamine oxidase inhibitors. [2006.05]
Effect of nerodilol, carvone and anethole on the in vitro transdermal delivery of selegiline hydrochloride. [2006.01]
Transdermal selegiline and intravenous cocaine: safety and interactions. [2004.02]
Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. [2003.01]
Selegiline transdermal system Somerset. [2002.08]
Oral versus transdermal selegiline: antidepressant-like activity in rats. [1999.07]
Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration. [1997.10]
Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. [1997.08]
Pressor response to tyramine after single 24-hour application of a selegiline transdermal system in healthy males. [1997.03]
Other possibly related research studies
Translating the evidence on atypical depression into clinical practice. [2007.04]
Translating the evidence on atypical depression into clinical practice. [2007]
Bipolar depression: a review of randomised clinical trials. [2007.01]
Advances in the treatment of depression. [2006.01]
Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update. [2006]
Alternatives to levodopa in the initial treatment of early Parkinson's disease. [2005]
Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. [2004.11]
Gateways to clinical trials. [2004.01]
Gateways to clinical trials. March 2003. [2003.03]
Gateways to Clinical Trials. [2002.09]
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. [2008.06.25]
Effect of MAO-B inhibition against ischemia-induced oxidative stress in the rat brain. Comparison with a rational antioxidant. [2008]
The effects of antidepressants in Parkinson's disease: a meta-analysis. [2008.05]
Protection against Parkinson's disease progression: clinical experience. [2008.04]
Treatment options in Alzheimer's disease: maximizing benefit, managing expectations. [2008]
[The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life] [2008.01.30]
The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B. [2008.05]
[Low dose pergolide induced systemic edema and pleural effusion in a patient with Parkinson's disease] [2008.02]
[Role of apoptosis in the kidney after reperfusion] [2008.02.17]
Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. [2007.12.01]
Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. [2008.04.15]
|